HLHS Subtypes #2 – MS/AA (Mitral Stenosis / Aortic Atresia)

Date
November 22, 2025
URL
https://x.com/WithAScalpel/status/1992206069259473356?s=20
Categories
HLHS

HLHS Subtypes – Mitral Stenosis / Aortic Atresia (MS/AA)

image

The mitral stenosis / aortic atresia (MS/AA) variant is one of the most characteristic and clinically challenging forms of hypoplastic left heart syndrome (HLHS). In contemporary surgical series it accounts for roughly 20–25% of HLHS cases and is repeatedly identified as a high-risk anatomic subgroup for both early and late outcomes.[1–3] Compared with other subtypes, MS/AA hearts tend to have the smallest ascending aorta, the highest burden of endocardial fibroelastosis (EFE), and a striking prevalence of ventriculo-coronary or coronary–LV fistulas.[1,3–5] These structural features underpin a physiology that is entirely ductal-dependent for systemic and coronary perfusion and particularly vulnerable to ischemic injury.

1. Anatomic Features

  1. Left ventricle (LV) and myocardium
    • The LV is typically small, hypertrophied, and poorly compliant, with a narrow, slit-like cavity.
    • Diffuse EFE is very common, producing a bright, fibrotic endocardial lining that further stiffens the ventricle and limits diastolic filling.[1,3]
    • Functionally, the LV behaves less like a useful pump and more like a pressurized fibroelastotic mass, which can distort septal geometry and impede RV filling.
  2. Mitral valve – Mitral stenosis
    • The mitral valve is patent but obstructed: leaflets are thickened, dysplastic, and partially fused, and the subvalvular apparatus is often foreshortened or tethered.
    • Diastolic inflow across the mitral valve is restricted, elevating left-atrial and pulmonary venous pressures even though the LV contributes little to systemic output.
  3. Aortic valve and ascending aorta – Aortic atresia
    • The aortic valve is completely atretic; no antegrade flow can exit the LV into the aorta.
    • The ascending aorta and arch are extremely hypoplastic, often thread-like on imaging and consistently smaller than in other HLHS subtypes.[2,4]
    • The coronary arteries arise from this tiny ascending aorta and are supplied only by retrograde flow from the ductal/arch circuit, not from LV ejection.
  4. Ductus arteriosus and great vessels
    • Systemic circulation is entirely ductal-dependent:
      • RV → main pulmonary artery → patent ductus arteriosus (PDA) → descending aorta → retrograde flow into the aortic arch, ascending aorta, and coronaries.
    • Any degree of ductal constriction can critically compromise systemic and coronary perfusion.
  5. Coronary circulation and fistulas
    • Coronary abnormalities are a hallmark of MS/AA.
      • Autopsy and registry data show LV–coronary or subepicardial coronary communications in more than half of MS/AA hearts, and these are strongly associated with Stage I mortality.[1,5]
      • A larger pathologic series confirmed coronary fistulous communications in ~16% of MS/AA specimens, a significantly higher rate than in other subtypes.[3]
    • Contemporary echocardiographic cohorts similarly report ventriculo-coronary connections in the majority of MS/AA patients, emphasizing that this anatomy is the rule rather than the exception.[4]
  6. Atrial septum and right ventricle
    • A generous atrial septal communication (ASD or PFO) is essential to decompress the hypertensive left atrium; restriction at this level rapidly produces pulmonary edema and severe hypoxemia.
    • The right ventricle (RV) is the sole functional pump, generating both pulmonary blood flow and, via the ductus, systemic and coronary perfusion.

2. Hemodynamics and Pathophysiology

The combination of mitral stenosis, aortic atresia, EFE, and coronary abnormalities produces a distinctive—and precarious—circulatory pattern:

  1. Ductal-dependent systemic and coronary output
    • All effective systemic blood flow originates from the RV and reaches the body through the PDA and descending aorta, with retrograde perfusion of the arch, ascending aorta, and coronaries.
    • There is no antegrade LV contribution to systemic output at any stage.
  2. Pulmonary venous and left-atrial hypertension
    • Restricted mitral inflow and a stiff, fibroelastotic LV cause marked elevation of left-atrial pressure.
    • If the ASD is restrictive, this pressure is transmitted to the pulmonary veins and capillaries, predisposing to pulmonary edema and early pulmonary vascular disease.
  3. Coronary perfusion vulnerability
    • Coronary flow depends on retrograde diastolic pressure in the tiny ascending aorta, which in turn depends on ductal patency and adequate systemic vascular resistance.
    • LV–coronary and coronary–LV fistulas complicate this physiology:
      • In utero they may help perfuse the hypertrophied LV, but postnatally they can create coronary “steal” when LV pressures fall—for example, after aggressive LV decompression or EFE resection.[1,5]
      • Autopsy series indicate that myocardial ischemia and necrosis are frequent in MS/AA, and often concentrated in the LV and systemic RV myocardium.[5]

Overall, MS/AA represents one of the most unstable coronary and systemic perfusion environments within the HLHS spectrum.

3. Clinical Profile and Outcome Data

Multiple independent series have shown that MS/AA is associated with worse outcomes at every stage of the single-ventricle pathway:

  • Early Norwood / Stage I outcomes
    • In a large single-center cohort (n=165), 23% of HLHS patients had MS/AA. Hospital mortality or need for transplantation after Stage I was 29% in MS/AA vs 7.9% in other anatomic subgroups, with LV–subepicardial coronary fistulas conferring a 50% mortality.[1]
    • Another center reported that, although MS/AA represented only 19% of Norwood patients, this group accounted for 50% of operative deaths and all interstage deaths; operative mortality was 29% vs 7% for all other HLHS forms.[2]
    • Some contemporary cohorts, using refined myocardial protection and shunt strategies, have achieved Stage I survival for MS/AA comparable to other subtypes, but outcomes remained strongly influenced by the presence and behavior of ventriculo-coronary connections.[2,6]
  • Interstage and transplant-free survival
    • Registry analyses have identified MS/AA as an independent risk factor for interstage mortality after Stage I palliation, even after adjustment for other clinical variables.[2,6]
  • Long-term outcomes after Fontan
    • A recent Fontan survivor study demonstrated that the AA/MS (MS/AA) subgroup had the lowest 17-year survival (~56%), compared with 74–79% for other anatomic variants.[7]
    • MS/AA patients had higher rates of ventricular failure, transplant, or death, suggesting that the combination of early ischemic injury, chronic RV pressure/volume load, and coronary abnormalities has lasting consequences.[7]

Taken together, these data justify viewing MS/AA as a distinctly high-risk phenotype, in which both Stage I management and long-term surveillance must be tailored around the risk of myocardial ischemia and ventricular failure.

4. Surgical Strategy

In contrast to the MS/AS subtype, where a minority of patients may be candidates for LV recruitment, MS/AA is functionally committed to a single-ventricle pathway. Key principles are:

4.1 Immediate neonatal management

  • Maintain ductal patency with continuous PGE₁ infusion, since both systemic and coronary flows are entirely ductal-dependent.
  • Avoid excessive pulmonary blood flow that can “steal” from systemic output; systemic vascular resistance and diastolic pressure are deliberately kept high enough to sustain coronary perfusion.
  • Ensure a non-restrictive atrial septal communication; balloon septostomy or stenting is warranted if there is any suggestion of pulmonary venous hypertension.

4.2 Initial procedural options

  1. Hybrid Stage I (bilateral pulmonary artery banding + ductal stenting or continued PGE₁)
    • Avoids cardiopulmonary bypass and arch reconstruction in fragile neonates with:
      • Tiny ascending aorta,
      • Extensive EFE,
      • Complex ventriculo-coronary connections.
    • Early single-center series have shown acceptable Stage I and early interstage survival with this strategy in high-risk HLHS, including MS/AA.[8]
    • Hybrid palliation buys time to:
      • Characterize coronary anatomy and LV fistulas in more detail,
      • Optimize nutrition and end-organ function before comprehensive Stage II or Norwood-type reconstruction.
  2. Conventional Norwood Stage I
    • Constructs a neo-aorta from the pulmonary root and hypoplastic ascending aorta, with extensive arch augmentation, and provides controlled pulmonary blood flow via a modified Blalock–Taussig shunt or RV–PA conduit.
    • In MS/AA, particular attention is paid to:
      • Myocardial protection during arrest and reperfusion,
      • Avoiding abrupt LV decompression in the presence of LV–coronary fistulas,
      • Maintaining adequate diastolic pressure post-operatively to protect coronary flow.[1,6]

4.3 Ongoing staged palliation

  • Bidirectional Glenn and subsequent Fontan completion follow standard single-ventricle principles, but in MS/AA:
    • Surveillance focuses heavily on systemic RV function, coronary perfusion, and arrhythmia burden.
    • Late ventricular failure is more common, and the threshold for considering mechanical circulatory support or transplant evaluation may be lower than in other HLHS subtypes.[7]

5. Practical Teaching Points

  • Label vs concept:

    • The name “mitral stenosis / aortic atresia” captures only part of the story. Clinically, the defining feature is complete dependence on ductal and retrograde coronary flow in the setting of a stiff, fibroelastotic LV and tiny ascending aorta.

  • The LV is not a recruitable systemic ventricle.

    • In MS/AA, the combination of aortic atresia, extreme aortic hypoplasia, heavy EFE, and frequent ventriculo-coronary fistulas essentially precludes a biventricular strategy. Efforts should be directed toward protecting the systemic RV and coronaries, not “training” the LV.

  • Coronary anatomy drives risk.

    • LV–coronary fistulas and abnormal coronary origins are powerful predictors of Stage I failure and autopsy-proven ischemic injury.[1,3,5] Every major management decision—choice of shunt, extent of LV decompression, hybrid vs Norwood—should be considered in terms of its impact on coronary perfusion.

  • Hybrid approaches can be particularly useful in MS/AA.

    • For neonates with tenuous coronary reserve or prohibitive surgical risk, bilateral PA banding plus ductal patency offers a way to stabilize the circulation, minimize ischemic insults, and reassess anatomy before committing to comprehensive reconstruction.[8]

In summary, the MS/AA subtype occupies a unique position within the HLHS spectrum: it combines severe inflow and outflow abnormalities of the LV with extreme ductal and coronary dependence and a high burden of EFE and coronary fistulas. These features mandate a carefully staged single-ventricle strategy, meticulous attention to myocardial perfusion from the fetal period through Fontan, and honest counseling of families about the elevated risk of ventricular failure and transplantation over the long term.

References

[1] Vida VL, Bacha EA, Larrazabal A, et al. Surgical outcome for patients with the mitral stenosis–aortic atresia variant of hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2008;135(2):339-346.

[2] Siehr SL, Maeda K, Connolly AA, et al. Mitral stenosis and aortic atresia—a risk factor for mortality after the modified Norwood operation in hypoplastic left heart syndrome. Ann Thorac Surg. 2016;101(1):162-167.

[3] Stephens EH, Gupta D, Bleiweis M, Backer CL, Anderson RH, Spicer DE. Coronary arterial abnormalities in hypoplastic left heart syndrome: pathologic characteristics of archived specimens. Semin Thorac Cardiovasc Surg. 2020;32(3):531-538.

[4] Wilson HC, Sood V, Romano JC, et al. Hypoplastic left heart syndrome with mitral stenosis and aortic atresia—echocardiographic findings and early outcomes. J Am Soc Echocardiogr. 2024;37(6):603-612.

[5] Nathan M, Williamson AK, Mayer JE, Bacha EA, Juraszek AL. Mortality in hypoplastic left heart syndrome: review of 216 autopsy cases of aortic atresia with attention to coronary artery disease. J Thorac Cardiovasc Surg. 2012;144(6):1301-1306.

[6] Sathanandam SK, Polimenakos AC, Roberson DA, et al. Mitral stenosis and aortic atresia in hypoplastic left heart syndrome: survival analysis after stage I palliation. Ann Thorac Surg. 2010;90(5):1599-1607.

[7] Moon J, Lancaster T, Sood V, et al. Long-term impact of anatomic subtype in hypoplastic left heart syndrome after Fontan completion. J Thorac Cardiovasc Surg. 2024;168(1):193-201.e3.

[8] Caldarone CA, Benson L, Holtby H, Li J, Redington AN, Van Arsdell GS. Initial experience with hybrid palliation for neonates with single-ventricle physiology. Ann Thorac Surg. 2007;84(4):1294-1300.